These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34771496)

  • 41. Uncovering the roles of microRNAs/lncRNAs in characterising breast cancer subtypes and prognosis.
    Li X; Truong B; Xu T; Liu L; Li J; Le TD
    BMC Bioinformatics; 2021 Jun; 22(1):300. PubMed ID: 34082714
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prioritizing breast cancer subtype related miRNAs using miRNA-mRNA dysregulated relationships extracted from their dual expression profiling.
    Hua L; Zhou P; Li L; Liu H; Yang Z
    J Theor Biol; 2013 Aug; 331():1-11. PubMed ID: 23619378
    [TBL] [Abstract][Full Text] [Related]  

  • 43. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
    Gasparini P; Cascione L; Fassan M; Lovat F; Guler G; Balci S; Irkkan C; Morrison C; Croce CM; Shapiro CL; Huebner K
    Oncotarget; 2014 Mar; 5(5):1174-84. PubMed ID: 24632568
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
    Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
    BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
    Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
    Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer.
    Prat A; Carey LA; Adamo B; Vidal M; Tabernero J; Cortés J; Parker JS; Perou CM; Baselga J
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25139534
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Integration of microRNA signatures of distinct mammary epithelial cell types with their gene expression and epigenetic portraits.
    Pal B; Chen Y; Bert A; Hu Y; Sheridan JM; Beck T; Shi W; Satterley K; Jamieson P; Goodall GJ; Lindeman GJ; Smyth GK; Visvader JE
    Breast Cancer Res; 2015 Jun; 17(1):85. PubMed ID: 26080807
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases.
    Sjödahl G; Eriksson P; Lövgren K; Marzouka NA; Bernardo C; Nordentoft I; Dyrskjøt L; Liedberg F; Höglund M
    Mod Pathol; 2018 Dec; 31(12):1869-1881. PubMed ID: 29967424
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A high-risk luminal A dominant breast cancer subtype with increased mobility.
    Guo L; Chen G; Zhang W; Zhou L; Xiao T; Di X; Wang Y; Feng L; Zhang K
    Breast Cancer Res Treat; 2019 Jun; 175(2):459-472. PubMed ID: 30778902
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Performance of Three-Biomarker Immunohistochemistry for Intrinsic Breast Cancer Subtyping in the AMBER Consortium.
    Allott EH; Cohen SM; Geradts J; Sun X; Khoury T; Bshara W; Zirpoli GR; Miller CR; Hwang H; Thorne LB; O'Connor S; Tse CK; Bell MB; Hu Z; Li Y; Kirk EL; Bethea TN; Perou CM; Palmer JR; Ambrosone CB; Olshan AF; Troester MA
    Cancer Epidemiol Biomarkers Prev; 2016 Mar; 25(3):470-8. PubMed ID: 26711328
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of unanimous immune subtypes for different hormone receptor phenotypes of human breast cancer with potential prognostic significance.
    Yu C; Zhou L; Zhang Q
    Int Immunopharmacol; 2021 May; 94():107473. PubMed ID: 33611062
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer.
    Klopfenstein Q; Derangère V; Arnould L; Thibaudin M; Limagne E; Ghiringhelli F; Truntzer C; Ladoire S
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083415
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MicroRNA Expression Profiling of Epithelial Ovarian Cancer Identifies New Markers of Tumor Subtype.
    Rattanapan Y; Korkiatsakul V; Kongruang A; Siriboonpiputtana T; Rerkamnuaychoke B; Chareonsirisuthigul T
    Microrna; 2020; 9(4):289-294. PubMed ID: 32703147
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multi-Omics Data Fusion for Cancer Molecular Subtyping Using Sparse Canonical Correlation Analysis.
    Qi L; Wang W; Wu T; Zhu L; He L; Wang X
    Front Genet; 2021; 12():607817. PubMed ID: 34367231
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A three-gene model to robustly identify breast cancer molecular subtypes.
    Haibe-Kains B; Desmedt C; Loi S; Culhane AC; Bontempi G; Quackenbush J; Sotiriou C
    J Natl Cancer Inst; 2012 Feb; 104(4):311-25. PubMed ID: 22262870
    [TBL] [Abstract][Full Text] [Related]  

  • 56. miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.
    Pessôa-Pereira D; Evangelista AF; Causin RL; da Costa Vieira RA; Abrahão-Machado LF; Santana IVV; da Silva VD; de Souza KCB; de Oliveira-Silva RJ; Fernandes GC; Reis RM; Palmero EI; Marques MMC
    BMC Cancer; 2020 Feb; 20(1):143. PubMed ID: 32087690
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MicroRNA involvement in the pathogenesis and management of breast cancer.
    Khoshnaw SM; Green AR; Powe DG; Ellis IO
    J Clin Pathol; 2009 May; 62(5):422-8. PubMed ID: 19398594
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy.
    Rodríguez-Martínez A; de Miguel-Pérez D; Ortega FG; García-Puche JL; Robles-Fernández I; Exposito J; Martorell-Marugan J; Carmona-Sáez P; Garrido-Navas MDC; Rolfo C; Ilyine H; Lorente JA; Legueren M; Serrano MJ
    Breast Cancer Res; 2019 Feb; 21(1):21. PubMed ID: 30728048
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
    Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
    Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differences in molecular features of triple-negative breast cancers based on the age at diagnosis.
    Gulbahce HE; Bernard PS; Weltzien EK; Factor RE; Kushi LH; Caan BJ; Sweeney C
    Cancer; 2018 Dec; 124(24):4676-4684. PubMed ID: 30311638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.